Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Completed
GlaxoSmithKline
Phase 3
2005-08-01
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting
opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or
to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan
with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on
frequency of bowel movements. Subjects will be required to: (1) track their bowel movements
and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Completed
Cubist Pharmaceuticals LLC
Phase 3
2005-08-01
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting
opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or
to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan
with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on
frequency of bowel movements. Subjects will be required to: (1) track their bowel movements
and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Completed
GlaxoSmithKline
Phase 3
2005-08-01
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting
opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms,
or to placebo. The primary objective of this phase 3 confirmatory study is to compare
alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is
based on frequency of bowel movements. Subjects will be required to: (1) track their bowel
movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
